In this interview, Jonathan Appleby discusses his appointment as the new Chief Scientific Officer of the Cell and Gene Therapy Catapult.
Dr Jonathan Appleby graduated from the University of Leeds (UK) with an honors degree in Genetics and a PhD from the Department of Biochemistry and Molecular Biology. He was Project Leader and Portfolio Manager at the GSK (UK) Centre of Excellence for External Drug Development before joining GSK’s Rare Diseases Unit. Dr Appleby is currently Chief Scientific Officer for Cell and Gene Therapy at the GSK Rare Diseases Unit where, among other things, he is Medicines Development Leader for Strimvelis®, the first autologous ex vivo CD34 stem cell gene therapy to gain EU Marketing approval. He will take up his appointment as Chief Scientific Officer of the Cell and Gene Therapy Catapult (CGT Catapult; London, UK) on 1 October 2018.